New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Vyome Holdings, Inc.

HIND

Healthcare Biotechnology

Vyome Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $319,700.00, up 24.4% from fiscal 2024.

Revenue
+67.6%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.20 0.25 −17.24%
Market cap
$10.2M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
4/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was 0.00% in Q3 FY26, the highest of these four quarters.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE3263.0%−235.8%−172.1%−71.8%
ROIC0.0%0.0%0.0%0.0%

Debt

Net debt is 6.49× a year’s EBITDA. Debt is 0.05× equity, against 0.07× in Q4 FY25.

Debt / equityNet debt / EBITDA
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Debt / equity0.1×0.0×0.0×0.1×
Net debt / EBITDA3.5×7.8×9.2×6.5×

Per share, from Q4 FY25

Since Q4 FY25, per share: revenue has fallen 59.9%; book value has grown 45.9%.

RevenueBook value
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue1.0×0.4×0.3×0.4×
Book value1.0×1.9×1.6×1.5×
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Piotroski F-Score

+8 more TTM periods

4 4 4 4
ROE
3,262.99% (235.80%) (172.10%) (71.85%)
ROA
(260.50%) (131.16%) (124.23%) (48.02%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(373.24%) (154.77%) (178.61%) (67.45%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(0.64) (0.74) (0.79) (0.64)
Free Cash Flow
(3.75) (4.98) (5.58) (4.49)
Other line items
Cash ROIC
(41.70%) (29.59%) (36.70%) (32.41%)
Accounts Payable Turnover
0.09 0.05 0.05 0.05
Average Days of Payables
4,649.96 5,713.24 6,335.40 4,936.88
Research and Development Expense of Revenue
183.99% 762.11% 1,225.81% 1,280.16%
Selling, General and Administrative Expense of Revenue
739.68% 1,690.77% 2,067.03% 1,614.95%
Share Based Compensation of Revenue
2,069.67% 4,345.22% 5,102.85% 212.53%
Interest Coverage
(71.30) (120.59) (286.58) (231.15)
Operating CF/Net income
0.37 0.46 0.49 1.19
Depreciation/Fixed assets
0.26 0.25 0.25 0.26
Capex/Depreciation
0.00 0.00 0.00 0.00
Revenue per Share
0.05 0.02 0.02 0.02
Operating CF per Share
(0.64) (0.74) (0.79) (0.64)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates · fundamentals updated Nov 18, 2026